Innovative Industrial Properties Inc vs Johnson & Johnson — how do they compare? Innovative Industrial Properties Inc trades at $64 (market cap $1.87B), while Johnson & Johnson trades at $248.46 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 320.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (11.81%). Which is the better fit depends on your goals.
| IIPR | JNJ | |
|---|---|---|
Market Cap | $1.87B | $598.96B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $267.24 |
52-Week Low | $44.58 | $164.36 |
Enterprise Value | $2.25B | $631.90B |
Dividend Yield | 11.81% | 2.15% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $64.35, down slightly today, amid a bullish technical trend with strong moving average support. The REIT reported mixed quarterly earnings, with a significant beat in Q4 2025 but a miss in Q1 2026, while maintaining a high dividend yield. Recent news highlights successful debt management and cannabis rescheduling progress as positive catalysts.
Outlook is cautiously optimistic given the strong balance sheet and regulatory tailwinds, but risks include revenue volatility and high dividend payout. Analyst sentiment is mixed with a slight Hold bias, reflecting concerns over near-term earnings consistency versus long-term growth potential in the cannabis real estate sector.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →